Endeavor

Combination Therapy Before Surgery Shows Promise for Aggressive Skin Cancer

Moffitt-led study explores how pairing lenvatinib and pembrolizumab strengthens immune response against Merkel cell carcinoma

Experimental Injectable Therapy Offers Nonsurgical Treatment of Common Skin Cancer

Phase 2 study led by Moffitt researchers finds VP-315 triggers strong local and systemic immune response against basal cell carcinoma

TIL Therapy Research Expanded to Bladder Cancer

Almost half of patients enrolled in a Moffitt trial responded to the cellular immunotherapy

Can Hybrid Immunotherapy Improve Solid Tumor Treatment?

Moffitt researchers test CAR-TIL cells combining tumor navigation and targeted attack

New Treatment Combines Electric Fields and Immunotherapy to Improve Survival for Glioblastoma Patients

Study shows promising results for patients with inoperable tumors, offering hope for better outcomes in one of the most aggressive forms of brain cancer

Newly Approved Cell Therapy Afami-Cel Shows Long-Term Tumor Control in Synovial Sarcoma

Phase 2 clinical trial data suggests the engineered T cells can stay active in the body for more than three years

New Cancer Vaccine May Boost Immunotherapy in Treating Lung Cancer

Phase 2 trial results suggest IO102-IO103 combined with pembrolizumab may enhance response rates in advanced lung cancer

A Novel Class of Therapeutic Biologics Shows Promise for HPV-Related Head and Neck Cancer

Combining two treatments may improve outcomes for patients with HPV 16–positive disease

Moffitt Experts’ Study Aims to Improve TIL Therapy Process

Tumor-infiltrating lymphocyte therapy is FDA approved to treat melanoma.